Open Access

Effect of ginsenoside‑Rg1 on experimental Parkinson's disease: A systematic review and meta‑analysis of animal studies

  • Authors:
    • Yi-Bo He
    • Yong-Lin Liu
    • Zheng-Dong Yang
    • Jia-Hong Lu
    • Yao Song
    • Yan-Ming Guan
    • Yi-Min Chen
  • View Affiliations

  • Published online on: March 25, 2021     https://doi.org/10.3892/etm.2021.9984
  • Article Number: 552
  • Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have reported that ginsenoside‑Rg1 (G‑Rg1) was able to mitigate the loss of dopaminergic neurons in animal models of Parkinson's disease (PD). The present study provided a systematic review and meta‑analysis of preclinical studies to pool current evidence on the effect of G‑Rg1 on neurogenesis in the treatment of PD. Eligible studies were identified through a search from six databases: PubMed, EMBASE, Web of Science, VIP, Chinese National Knowledge Infrastructure and the Wanfang database. Primary outcomes were tyrosine hydroxylase (TH)‑positive cells in the nigra, Nissl staining‑positive cells in the nigra, pole test time and dopamine (DA) levels in the striatum. A total of 18 eligible studies were identified, involving 343 animals. Of these, 13 reported a significant relationship between G‑Rg1 and improved TH‑positive cells in the nigra compared with the control group (P<0.00001). Furthermore, 3 studies reported a significant relationship between G‑Rg1 and improved Nissl‑positive cells in the nigra compared with the control group (P<0.00001). In addition, 4 studies reported a significant effect of G‑Rg1 to reduce the total pole test time compared with that in the control group (P=0.001). A total of 3 studies indicated a significant association between G‑Rg1 and improved DA levels in the striatum compared with the control group (P<0.00001). These results suggested that G‑Rg1 has positive effects in attenuating damage in models of PD, and thus, it is a potential candidate neuroprotective drug for human PD.
View Figures
View References

Related Articles

Journal Cover

June-2021
Volume 21 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
He Y, Liu Y, Yang Z, Lu J, Song Y, Guan Y and Chen Y: Effect of ginsenoside‑Rg1 on experimental Parkinson's disease: A systematic review and meta‑analysis of animal studies. Exp Ther Med 21: 552, 2021
APA
He, Y., Liu, Y., Yang, Z., Lu, J., Song, Y., Guan, Y., & Chen, Y. (2021). Effect of ginsenoside‑Rg1 on experimental Parkinson's disease: A systematic review and meta‑analysis of animal studies. Experimental and Therapeutic Medicine, 21, 552. https://doi.org/10.3892/etm.2021.9984
MLA
He, Y., Liu, Y., Yang, Z., Lu, J., Song, Y., Guan, Y., Chen, Y."Effect of ginsenoside‑Rg1 on experimental Parkinson's disease: A systematic review and meta‑analysis of animal studies". Experimental and Therapeutic Medicine 21.6 (2021): 552.
Chicago
He, Y., Liu, Y., Yang, Z., Lu, J., Song, Y., Guan, Y., Chen, Y."Effect of ginsenoside‑Rg1 on experimental Parkinson's disease: A systematic review and meta‑analysis of animal studies". Experimental and Therapeutic Medicine 21, no. 6 (2021): 552. https://doi.org/10.3892/etm.2021.9984